{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-186994","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.644720+00:00","generated_at":"2026-05-17T10:28:30.530270+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MannKind to acquire scPharmaceuticals for $5.35/share plus CVR up to $1.00/share","bullets":["Offer price: $5.35 cash + one contingent value right (CVR) per share; CVR milestones up to $1.00 aggregate.","CVR milestones: FDA approval of SCP-111 injection by June 30, 2027 (Milestone 1) and $110M+ net sales of specified products by Dec 31, 2026 (Milestone 2).","Principal stockholders holding ~11.5% of SCPH shares have agreed to tender and support the deal.","MannKind obtained $175M incremental delayed draw term loan from Blackstone to finance transaction costs; will repay ~$81M of SCPH's Perceptive debt upon close.","Strategic rationale: acquisition of FUROSCIX (approved for heart failure and chronic kidney disease) to expand into cardiorenal medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-186994","json":"https://secwatch.observer/filing/0001193125-25-186994.json","markdown":"https://secwatch.observer/filing/0001193125-25-186994.md","text":"https://secwatch.observer/filing/0001193125-25-186994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/0001193125-25-186994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:28:30.530270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}